March 7, 2019
Researchers at Purdue Center for Cancer Research develop innovative, more cost-effective method to make drugs
WEST LAFAYETTE, Ind. – The Food and Drug Administration wants the pharmaceutical industry to get away from making drugs using the traditional batch method and switch to a more modern process known as continuous manufacturing.
The FDA put out a statement on Feb. 26 saying the continuous process allows manufacturers to more easily scale operations to meet demand and should help reduce drug shortages. The statement also said continuous manufacturing can provide a more robust, lower cost and diverse supply of drug products.
David H. Thompson, a professor in Purdue’s Department of Chemistry and a member of the Purdue University Center for Cancer Research, has written a research paper published in Organic Process Research and Development about how to make a generic form of lomustine, prescribed to people with Hodgkin lymphoma and certain brain cancers. But the continuous manufacturing process described in the paper is not just limited to lomustine. It can be applied to many other products. The ability to reduce production costs has the potential to allow for more agile and cost effective production of many life-saving medicines. A video is available here.
The goal is to improve manufacturing flexibility, enhance quality and uniformity, while lowering the costs for patients. This is especially important for achieving the anticipated benefits of personalized and regenerative medicine products that target tiny patient populations that currently make their manufacture on large-scale cost-prohibitive.
Continuous manufacturing is an alternative to “batch” production where the drug product is produced continuously through a sequence of coupled flow reactors. Thompson and his team selected continuous manufacture for lomustine production because of improved quality monitoring throughout the manufacturing process. In addition, this approach can also reduce production costs by utilizing a safer and smaller production facility.
Thompson began working on applying his innovative continuous manufacturing process for lomustine after reading an article written by Dr. Henry Friedman, a well-known Duke University neuro-oncologist, in The Cancer Letter in September 2017. The article wrote about how the cost of lomustine had risen dramatically.
Thompson approached his team and said they needed to do something.
“We have to help the people impacted by this problem. We must show how to make lomustine quickly and cheaply, to provide an alternative for people in need,” he said.
Within six months, Thompson’s team developed a method to make lomustine at a rate equivalent to one dose every two hours using continuous manufacture. His group is now developing methods to scale up the production rate.
“All of this is happening in a space that is the size of a small desk. A very small footprint,” Thompson said.
Thompson said the speed of development was aided by Purdue’s Bindley Bioscience Center at Purdue’s Discovery Park because this resource brings together researchers from different disciplines, and makes available key instrumentation.
Not satisfied with simply demonstrating a solution, Thompson has joined with credible industry partners and founded Continuity Pharma to translate its process to the scalable production of lomustine.
This work aligns with Purdue's Giant Leaps celebration, celebrating the global advancements in health, longevity and quality of life as part of Purdue’s 150th anniversary. Health is one of the four themes of the yearlong celebration’s Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues.
The researchers have filed for a patent on their continuous synthesis process to make lomustine with the help of Purdue’s Office of Technology Commercialization.
About Purdue Office of Technology Commercialization
The Purdue Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities. The office is managed by the Purdue Research Foundation, which received the 2016 Innovation and Economic Prosperity Universities Award for Innovation from the Association of Public and Land-grant Universities. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at email@example.com. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at firstname.lastname@example.org.
Writer: Zeina Kayyali, email@example.com
Purdue Research Foundation contact: Tom Coyne, 765-588-1044, firstname.lastname@example.org
Source: David Thompson, email@example.com
Note to Journalists: A copy of the research paper is available from Tom Coyne, 765-588-1044, firstname.lastname@example.org
Rapid on-Demand Synthesis of Lomustine under Continuous Flow Conditions
Zinia Jaman, Tiago J. P. Sobreira, Ahmed Mufti, Christina R. Ferreira, R. Graham Cooks, and David H. Thompson
Lomustine, an important agent for treatment of brain tumors and Hodgkin’s lymphoma has been synthesized using continuous flow methodology. Desorption electrospray ionization mass spectrometry (DESI-MS) was used to quickly explore a large number of reaction conditions for one of the reaction steps and guide the efficient translation of optimized conditions to continuous lomustine production. Using only four inexpensive commercially available starting materials and a total residence time of 9 min, lomustine was prepared via a linear sequence of two chemical reactions performed separately in two telescoped flow reactors. Sequential offline extraction and filtration results in a 63% overall yield of pure lomustine at a production rate of 110 mg/h. The primary advantages of this approach are the rapid manufacture of lomustine with two telescoped steps to avoid isolation and purification of a labile intermediate and the mild conditions used in the nitrosylation step, thereby significantly increasing the purity and yield of this active pharmaceutical ingredient.